Drug intelligence / Profile preview

EC33

Development stage: Preclinical
Lead developer: Atos
Modality: Small Molecules
Administration: Intracerebroventricular, Intravenous, Oral

Overview

EC33 is a **small molecule inhibitor** that acts as an **aminopeptidase A (APA) inhibitor**, and is under the category of **angiotensin II receptor antagonists**. It was initially developed by Atos SE as a potential antihypertensive therapy due to its capacity to significantly decrease arterial pressure by inhibiting APA, which plays a key role in the renin-angiotensin system by converting angiotensin II to angiotensin III[2][3].

Targets

ENPEP (Glutamyl Aminopeptidase)

Beyond the preview

Go deeper on EC33.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EC33.

Explore the full profile